Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Net Income (2020 - 2022)

Atea Pharmaceuticals has reported Net Income over the past 3 years, most recently at -$34.4 million for Q4 2022.

  • Quarterly results put Net Income at -$34.4 million for Q4 2022, down 129.4% from a year ago — trailing twelve months through Dec 2022 was -$115.9 million (down 195.64% YoY), and the annual figure for FY2025 was -$158.3 million, up 5.96%.
  • Net Income for Q4 2022 was -$34.4 million at Atea Pharmaceuticals, down from -$8.1 million in the prior quarter.
  • Over the last five years, Net Income for AVIR hit a ceiling of $117.1 million in Q4 2021 and a floor of -$42.1 million in Q1 2022.
  • Median Net Income over the past 3 years was -$9.0 million (2020), compared with a mean of -$472166.7.
  • Biggest five-year swings in Net Income: skyrocketed 870.14% in 2021 and later plummeted 2136.06% in 2022.
  • Atea Pharmaceuticals' Net Income stood at $20.7 million in 2020, then skyrocketed by 467.06% to $117.1 million in 2021, then tumbled by 129.4% to -$34.4 million in 2022.
  • The last three reported values for Net Income were -$34.4 million (Q4 2022), -$8.1 million (Q3 2022), and -$31.3 million (Q2 2022) per Business Quant data.